Literature DB >> 18662513

Idiopathic inflammatory myopathy: treatment options.

Stephen J DiMartino1.   

Abstract

Idiopathic inflammatory myopathy (IIM) comprises a group of rare disorders in which there is an immune-mediated attack on skeletal muscle, the consequence of which is muscle damage and weakness in the patient. As in other inflammatory diseases, the general approach to therapy is use of immunosuppressive agents. Many options exist for IIM treatment, but therapeutic approaches are based mostly on empirical evidence and small studies, many of which are uncontrolled. Recently, new agents have been designed to target specific components of the immune response, and they offer hope for more effective or safer IIM therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662513     DOI: 10.1007/s11926-008-0051-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  49 in total

1.  Refractory polymyositis responding to infliximab: extended follow-up.

Authors:  I Labioche; E Liozon; B Weschler; V Loustaud-Ratti; P Soria; E Vidal
Journal:  Rheumatology (Oxford)       Date:  2004-04       Impact factor: 7.580

2.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Authors:  Patrick Cherin; S Pelletier; A Teixeira; P Laforet; T Genereau; A Simon; T Maisonobe; B Eymard; S Herson
Journal:  Arthritis Rheum       Date:  2002-02

Review 3.  Treatment of polymyositis and dermatomyositis.

Authors:  M Dalakas
Journal:  Curr Opin Rheumatol       Date:  1989-12       Impact factor: 5.006

4.  Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies.

Authors:  S Matsubara; Y Sawa; M Takamori; H Yokoyama; H Kida
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

5.  Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases.

Authors:  A C Gelber; H C Nousari; F M Wigley
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

Review 6.  Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.

Authors:  K A Qushmaq; A Chalmers; J M Esdaile
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

Review 7.  Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations.

Authors:  Gerald J D Hengstman; Baziel G M van Engelen; Walther J van Venrooij
Journal:  Curr Opin Rheumatol       Date:  2004-11       Impact factor: 5.006

8.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors:  M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

9.  Dermatopolymyositis and other connective tissue diseases: a review of 105 cases.

Authors:  K E Tymms; J Webb
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

Review 10.  Differential diagnosis of idiopathic inflammatory myopathies.

Authors:  Alan N Baer
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

View more
  2 in total

Review 1.  Use of Natural Products in Asthma Treatment.

Authors:  Lucas Amaral-Machado; Wógenes N Oliveira; Susiane S Moreira-Oliveira; Daniel T Pereira; Éverton N Alencar; Nicolas Tsapis; Eryvaldo Sócrates T Egito
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-13       Impact factor: 2.629

2.  Embelin Alleviates Severe Airway Inflammation in OVA-LPS-Induced Rat Model of Allergic Asthma.

Authors:  Shazalyana Azman; Mahendran Sekar; Suzana Wahidin; Siew Hua Gan; Jaishree Vaijanathappa; Srinivasa Reddy Bonam; Mallika Alvala; Pei Teng Lum; Vandana Thakur; Jayesh V Beladiya; Anita A Mehta
Journal:  J Asthma Allergy       Date:  2021-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.